Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

At Pfizer's share price at the time of this writing ($22.87), you'd need to invest roughly $132,966 to generate $10,000 in ...

Pfizer expanded its cost-cutting plans and posted first-quarter profit above estimates, despite a decline in sales driven by falling revenue from its Covid pill, according to CNBC. The company ...

Pfizer (NYSE:PFE) surged about 3% on Tuesday ... Management reaffirmed its full-year 2025 outlook, noting that the forecast does not currently include any potential impact related to future ...

Pfizer reported weaker first-quarter results on Tuesday, with revenue falling short of Wall Street estimates, but earnings beating expectations. The US drugmaker reaffirmed its full-year 2025 ...

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, "which we are unable to predict at this time." ...

Pfizer ( PFE) reported mixed first quarter earnings Tuesday, as the company struggles to gain investor interest in its ...

"We are currently trending towards the upper end of our 2025 adjusted diluted EPS guidance range." Pfizer (PFE) Chief Executive Albert Bourla stuck to the company's profit and revenue forecast for ...

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped ... Pfizer did not revise its outlook. The company maintained its full-year 2025 outlook ...